On May, 8 Xenon Pharmaceuticals Inc. (XENE) EPS Estimated At $-0.48

April 17, 2018 - By Benjamin Allen

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Corporate Logo

On May, 8. Investors wait Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to publish its quarterly earnings, according to RTT. Analysts predict 11.63 % diference or $-0.48 from the $-0.43 EPS from 2017. After $-0.45 EPS report last quarter, Wall Street now predicts 6.67 % negative EPS growth of Xenon Pharmaceuticals Inc.. XENE reached $5.45 on during the last trading session after $0.15 change.Xenon Pharmaceuticals Inc. is uptrending after having risen 4.40% since April 17, 2017. XENE has 205,149 volume or 170.19% up from normal. The stock underperformed the S&P 500 by 7.15%.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada.The firm is worth $77.23 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.Last it reported negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.